5du3
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='5du3' size='340' side='right'caption='[[5du3]], [[Resolution|resolution]] 2.10Å' scene=''> | <StructureSection load='5du3' size='340' side='right'caption='[[5du3]], [[Resolution|resolution]] 2.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5du3]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[5du3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DU3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5DU3 FirstGlance]. <br> |
| - | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5du3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5du3 OCA], [https://pdbe.org/5du3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5du3 RCSB], [https://www.ebi.ac.uk/pdbsum/5du3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5du3 ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/IC1_HUMAN IC1_HUMAN] Defects in SERPING1 are the cause of hereditary angioedema (HAE) [MIM:[https://omim.org/entry/106100 106100]; also called hereditary angioneurotic edema (HANE). HAE is an autosomal dominant disorder characterized by episodic local subcutaneous edema and submucosal edema involving the upper respiratory and gastrointestinal tracts. HAE due to C1 esterase inhibitor deficiency is comprised of two clinically indistinguishable forms. In HAE type 1, representing 85% of patients, serum levels of C1 esterase inhibitor are less than 35% of normal. In HAE type 2, the levels are normal or elevated, but the protein is non-functional.<ref>PMID:12773530</ref> <ref>PMID:7814636</ref> <ref>PMID:3178731</ref> <ref>PMID:2365061</ref> <ref>PMID:2296585</ref> <ref>PMID:2118657</ref> [:]<ref>PMID:1451784</ref> <ref>PMID:1363816</ref> <ref>PMID:8172583</ref> <ref>PMID:7883978</ref> <ref>PMID:8529136</ref> <ref>PMID:8755917</ref> <ref>PMID:14635117</ref> <ref>PMID:16409206</ref> <ref>PMID:22994404</ref> |
== Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/IC1_HUMAN IC1_HUMAN] Activation of the C1 complex is under control of the C1-inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein.<ref>PMID:8495195</ref> |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 24: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Homo sapiens]] |
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Dijk | + | [[Category: Dijk M]] |
| - | [[Category: Giannetti | + | [[Category: Giannetti BM]] |
| - | [[Category: Holkers | + | [[Category: Holkers J]] |
| - | [[Category: Pannu | + | [[Category: Pannu NS]] |
| - | + | [[Category: Voskamp P]] | |
| - | [[Category: Voskamp | + | [[Category: Waterreus WJ]] |
| - | [[Category: Waterreus | + | [[Category: Van Veen HA]] |
| - | [[Category: | + | |
| - | + | ||
Current revision
Active form of human C1-inhibitor
| |||||||||||
